Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia

Phase 3 Terminated 95 enrolled Medical University of Vienna Krankenhaus Barmherzige Schwestern Linz · collab Medical University Innsbruck · collab Medical University of Graz · collab Salzburger Landeskliniken · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the non-inferiority of a topical Imiquimod therapy in patients with persistent CIN 2/3 when compared to standard therapy, i.e. conization A randomized, controlled, non-inferiority AGO-Austria trial

Timeline

Start: 2013-05
Primary completion: 2017-09
Completion: 2018-01

Publications

Polterauer S, Reich O, Widschwendter A, Hadjari L, Bogner G, Reinthaller A, Joura E, Trutnovsky G, Ciresa-Koenig A, Ganhoer-Schimboeck J, Boehm I, Berger R, Langthaler E, Aberle SW, Heinze G, Gleiss A, Grimm C. Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial. Gynecol Oncol. 2022 Apr;165(1):23-29. doi: 10.1016/j.ygyno.2022.01.033. Epub 2022 Feb 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imiquimod	Other / unclassified	—	Topical

Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia

Summary

Timeline

Publications

Drugs

Indications